Monitor for future licensing or partnership announcements as preclinical data emerges; no near-term revenue catalyst. The activist filing (SC 13D/A 16 days prior) adds context but does not change the early-stage nature of this deal.
Price Chart
Executive Summary
CDT Equity announced a partnership with QIMA Life Sciences to explore tapinarof (VTAMA®) combinations in autoimmune skin diseases, including vitiligo. The deal leverages QIMA's human skin tissue access for preclinical studies, aiming to develop a second-generation tapinarof product. No financial terms were disclosed, and the press release contains no revenue, earnings, or guidance data.
Key Facts
- Partnership with QIMA Life Sciences to study tapinarof (VTAMA®) combinations in psoriatic and vitiligo patient skin.
- VTAMA® is described as the number one branded topical treatment in the US.
- Vitiligo affects ~0.5%–2.0% of global population; global vitiligo drug market estimated at ~$2.6B in 2025, projected to reach $6.6B by 2030.
- No financial terms, milestone payments, or revenue guidance disclosed.
- Initial studies focus on tapinarof solid-form and method-of-use patents in combination with other drugs.
Financial Impact
No financial terms disclosed; vitiligo market cited as $2.6B (2025) to $6.6B (2030) but no direct revenue impact for CDT stated.
Risk Factors
- Preclinical studies may not translate to clinical success or regulatory approval.
- No disclosed financial commitment or milestone structure limits visibility into near-term value.
- CDT's history of reverse stock split and Nasdaq listing risks (noted in forward-looking statements) adds execution uncertainty.
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3364583 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 27, 2026 today | SC 13G/A | $0.0837 | awaiting T+20 | awaiting T+20 | $0.0800 (−4.42%) |
Oct 27, 2026 today | DEF 14A | $0.0890 | awaiting T+20 | awaiting T+20 | $0.0800 (+10.11%) |
Oct 27, 2026 today | SC 13D/A | $0.0890 | awaiting T+20 | awaiting T+20 | $0.0800 (−10.11%) |
Oct 27, 2026 today | 3 | $0.0819 | awaiting T+20 | awaiting T+20 | $0.0800 (−2.32%) |
Oct 27, 2026 today | 8-K | $0.0982 | awaiting T+20 | awaiting T+20 | $0.0800 (+18.53%) |
Oct 13, 2026 14d ago | 8-K | $0.4500 | awaiting T+20 | awaiting T+20 | $0.0800 (+82.22%) |
Oct 8, 2026 19d ago | SC 13G/A | $0.7180 | awaiting T+20 | awaiting T+20 | $0.0800 (+88.86%) |
Oct 7, 2026 20d ago | SC 13G | $0.8000 | awaiting T+20 | awaiting T+20 | $0.0800 (−90.00%) |
Oct 7, 2026 20d ago | SC 13G/A | $0.8000 | awaiting T+20 | awaiting T+20 | $0.0800 (+90.00%) |
Oct 7, 2026 20d ago | SC 13G/A | $0.8000 | awaiting T+20 | awaiting T+20 | $0.0800 (+90.00%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers